Correction to: Budget Impact Analysis of Fidaxomicin Versus Vancomycin for the Treatment of Clostridioides difficile Infection in the United States

Detalles Bibliográficos
Autores principales: Jiang, Yiling, Sarpong, Eric M., Sears, Pamela, Obi, Engels N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Correction
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8847657/
https://www.ncbi.nlm.nih.gov/pubmed/35034290
http://dx.doi.org/10.1007/s40121-021-00583-8
_version_ 1784652090892615680
author Jiang, Yiling
Sarpong, Eric M.
Sears, Pamela
Obi, Engels N.
author_facet Jiang, Yiling
Sarpong, Eric M.
Sears, Pamela
Obi, Engels N.
author_sort Jiang, Yiling
collection PubMed
description
format Online
Article
Text
id pubmed-8847657
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer Healthcare
record_format MEDLINE/PubMed
spelling pubmed-88476572022-02-23 Correction to: Budget Impact Analysis of Fidaxomicin Versus Vancomycin for the Treatment of Clostridioides difficile Infection in the United States Jiang, Yiling Sarpong, Eric M. Sears, Pamela Obi, Engels N. Infect Dis Ther Correction Springer Healthcare 2022-01-16 2022-02 /pmc/articles/PMC8847657/ /pubmed/35034290 http://dx.doi.org/10.1007/s40121-021-00583-8 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by-nc/4.0/ Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Correction
Jiang, Yiling
Sarpong, Eric M.
Sears, Pamela
Obi, Engels N.
Correction to: Budget Impact Analysis of Fidaxomicin Versus Vancomycin for the Treatment of Clostridioides difficile Infection in the United States
title Correction to: Budget Impact Analysis of Fidaxomicin Versus Vancomycin for the Treatment of Clostridioides difficile Infection in the United States
title_full Correction to: Budget Impact Analysis of Fidaxomicin Versus Vancomycin for the Treatment of Clostridioides difficile Infection in the United States
title_fullStr Correction to: Budget Impact Analysis of Fidaxomicin Versus Vancomycin for the Treatment of Clostridioides difficile Infection in the United States
title_full_unstemmed Correction to: Budget Impact Analysis of Fidaxomicin Versus Vancomycin for the Treatment of Clostridioides difficile Infection in the United States
title_short Correction to: Budget Impact Analysis of Fidaxomicin Versus Vancomycin for the Treatment of Clostridioides difficile Infection in the United States
title_sort correction to: budget impact analysis of fidaxomicin versus vancomycin for the treatment of clostridioides difficile infection in the united states
topic Correction
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8847657/
https://www.ncbi.nlm.nih.gov/pubmed/35034290
http://dx.doi.org/10.1007/s40121-021-00583-8
work_keys_str_mv AT jiangyiling correctiontobudgetimpactanalysisoffidaxomicinversusvancomycinforthetreatmentofclostridioidesdifficileinfectionintheunitedstates
AT sarpongericm correctiontobudgetimpactanalysisoffidaxomicinversusvancomycinforthetreatmentofclostridioidesdifficileinfectionintheunitedstates
AT searspamela correctiontobudgetimpactanalysisoffidaxomicinversusvancomycinforthetreatmentofclostridioidesdifficileinfectionintheunitedstates
AT obiengelsn correctiontobudgetimpactanalysisoffidaxomicinversusvancomycinforthetreatmentofclostridioidesdifficileinfectionintheunitedstates

Ejemplares similares